Cargando…
The genomic architecture of antimalarial drug resistance
Plasmodium falciparum and Plasmodium vivax, the two protozoan parasite species that cause the majority of cases of human malaria, have developed resistance to nearly all known antimalarials. The ability of malaria parasites to develop resistance is primarily due to the high numbers of parasites in t...
Autores principales: | Cowell, Annie N, Winzeler, Elizabeth A |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6859814/ https://www.ncbi.nlm.nih.gov/pubmed/31119263 http://dx.doi.org/10.1093/bfgp/elz008 |
Ejemplares similares
-
Exploration of the Plasmodium falciparum Resistome and Druggable Genome Reveals New Mechanisms of Drug Resistance and Antimalarial Targets
por: Cowell, Annie, et al.
Publicado: (2018) -
Drug resistance genomics of the antimalarial drug artemisinin
por: Winzeler, Elizabeth A, et al.
Publicado: (2014) -
Advances in omics-based methods to identify novel targets for malaria and other parasitic protozoan infections
por: Cowell, Annie N., et al.
Publicado: (2019) -
The antimalarial resistome – finding new drug targets and their modes of action
por: Carolino, Krypton, et al.
Publicado: (2020) -
Antimalarial drug discovery: progress and approaches
por: Siqueira-Neto, Jair L, et al.
Publicado: (2023)